» Articles » PMID: 10444002

The Humanized Anti-HM1.24 Antibody Effectively Kills Multiple Myeloma Cells by Human Effector Cell-mediated Cytotoxicity

Overview
Journal Mol Immunol
Date 1999 Aug 12
PMID 10444002
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A mouse monoclonal antibody, anti-HM1.24 (IgG2a/kappa), binds to a surface antigen preferentially overexpressed on multiple myeloma (MM) cells, and exhibits potent antitumor cell activity against MM cells by antibody-dependent cell-mediated cytotoxicity (ADCC). To develop an antibody-based immunotherapy against MM, a humanized anti-HM1.24 antibody, in which all FRs correspond to naturally processed human FRs, has been successfully constructed with the aid of both the hybrid variable region and two-step design methods. This humanized anti-HM1.24 antibody (IgG1/kappa) is able to effectively induce ADCC against human myeloma KPMM2 and ARH77 cells in the presence of human PBMCs as effectively as a chimeric anti-HM1.24 antibody. The humanized anti-HM1.24 antibody, therefore, could be expected as a potent immunotherapeutic agent for MM patients.

Citing Articles

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.

Yoon A, Lee S, Lee S, Lim S, Park Y, Song E Biomolecules. 2020; 10(3).

PMID: 32143496 PMC: 7175222. DOI: 10.3390/biom10030399.


CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.

Gong S, Osei E, Kaplan D, Chen Y, Meyerson H Int J Clin Exp Pathol. 2015; 8(2):1613-21.

PMID: 25973046 PMC: 4396245.


Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.

Mahauad-Fernandez W, Borcherding N, Zhang W, Okeoma C PLoS One. 2015; 10(4):e0123931.

PMID: 25860442 PMC: 4393144. DOI: 10.1371/journal.pone.0123931.


Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.

Harada T, Ozaki S Biomed Res Int. 2014; 2014:965384.

PMID: 25143955 PMC: 4124849. DOI: 10.1155/2014/965384.


Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.

Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M PLoS One. 2014; 8(12):e83905.

PMID: 24386306 PMC: 3873421. DOI: 10.1371/journal.pone.0083905.